FDA Approves Novel Targeted Therapy for Rare Blood Cancer

Published Date: 29 May 2026

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The pandemic had little impact on mental health symptoms.

2.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

3.

ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology

4.

Smoker's Painless Skin Nodules Flag a Fatal Diagnosis

5.

In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot